Applied therapeutics receives orphan medicinal product designation from the ema for at-007 for treatment of galactosemia

New york, june 03, 2022 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced designation of at-007 (gavorestat) as an orphan medicinal product by the european medicines agency (ema) for treatment of galactosemia (galactosaemia).
APLT Ratings Summary
APLT Quant Ranking